Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Hikma Pharmaceuticals PLC

Healthcare GB HIK

1416.0GBX
-5.0(0.35%)

Last update at 2026-06-03T15:35:00Z

Day Range

1414.001439.00
LowHigh

52 Week Range

1153.732071.97
LowHigh

Fundamentals

  • Previous Close 1421.00
  • Market Cap2842.79M
  • Volume744095
  • P/E Ratio9.73
  • Dividend Yield6.53%
  • EBITDA842.00M
  • Revenue TTM3349.00M
  • Revenue Per Share TTM15.18
  • Gross Profit TTM 1457.00M
  • Diluted EPS TTM1.35

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 529.89M 455.00M 281.00M 233.00M 544.00M
Minority interest -5.00000M -3.00000M -2.00000M -3.00000M 1.00M
Net income 410.43M 359.00M 190.00M 188.00M 421.00M
Selling general administrative 566.00M 568.00M 638.00M 509.00M 488.00M
Selling and marketing expenses - 94.00M 6.00M - -
Gross profit 1369.13M 1415.00M 1407.00M 1238.00M 1301.00M
Reconciled depreciation 238.00M 197.00M 259.00M 372.00M 145.00M
Ebit 637.09M 608.00M 619.00M 507.00M 582.00M
Ebitda 853.54M 787.00M 791.00M 700.00M 735.00M
Depreciation and amortization 216.45M 179.00M 172.00M 193.00M 153.00M
Non operating income net other - - - - -
Operating income 637.09M 612.00M 367.00M 507.00M 582.00M
Other operating expenses 2782.17M 2515.00M 2508.00M 2035.00M 1994.00M
Interest expense 108.22M 75.00M 90.00M 77.00M 69.00M
Tax provision 112.00M 93.00M 89.00M 42.00M 124.00M
Interest income 6.00M 8.00M 7.00M 3.00M 30.00M
Net interest income -91.00000M -80.00000M -83.00000M -52.00000M -39.00000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 114.35M 93.00M 89.00M 42.00M 124.00M
Total revenue 3419.26M 3127.00M 2875.00M 2517.00M 2553.00M
Total operating expenses 732.04M 803.00M 1040.00M 756.00M 742.00M
Cost of revenue 2050.13M 1712.00M 1468.00M 1279.00M 1252.00M
Total other income expense net -107.20293M -157.00000M -86.00000M -274.00000M -38.00000M
Discontinued operations - - - - -
Net income from continuing ops 407.00M 362.00M 192.00M 191.00M 420.00M
Net income applicable to common shares - - - 188.00M 421.00M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Total assets 5673.07M 5133.00M 4680.00M - 4471.00M
Intangible assets 777.28M 774.00M 712.00M - 735.00M
Earning assets - - - - -
Other current assets 104.04M 159.00M 191.00M - 110.00M
Total liab 3066.12M 2812.00M 2471.00M - 2323.00M
Total stockholder equity 2593.94M 2310.00M 2198.00M - 2135.00M
Deferred long term liab - - - - -
Other current liab 624.23M 889.00M 795.00M - 638.00M
Common stock 40.01M 40.00M 40.00M - 40.00M
Capital stock 40.00M 40.00M 40.00M - 40.00M
Retained earnings 2556.93M 2362.00M 2158.00M - 2092.00M
Other liab - - - - 111.00M
Good will 393.14M 382.00M 388.00M - 389.00M
Other assets - - - - 215.00M
Cash 328.12M 188.00M 205.00M - 270.00M
Cash and equivalents - - - - -
Total current liabilities 1453.53M 1978.00M 1339.00M - 1077.00M
Current deferred revenue - - 226.00M - -
Net debt 1321.48M 1118.00M 986.00M - 1013.00M
Short term debt 114.04M 653.00M 161.00M - 148.00M
Short long term debt 106.00M 642.00M 150.00M - 139.00M
Short long term debt total 1649.60M 1306.00M 1191.00M - 1283.00M
Other stockholder equity 282.10M -92.00000M 282.00M - 3.00M
Property plant equipment - - - - 1081.00M
Total current assets 2643.96M 2263.00M 2100.00M - 1999.00M
Long term investments - - - - -
Net tangible assets - - - - 1011.00M
Short term investments 26.01M 25.00M 24.00M - 22.00M
Net receivables 1079.39M 905.00M 789.00M - 843.00M
Long term debt 1445.00M 607.00M 975.00M - 1074.00M
Inventory 1106.40M 986.00M 891.00M - 776.00M
Accounts payable 715.26M 358.00M 309.00M - 291.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -285.10382M - -282.00000M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 92.03M 33.00M 274.00M - 22.00M
Deferred long term asset charges - - - - -
Non current assets total 3029.10M 2870.00M 2580.00M - 2472.00M
Capital lease obligations 53.00M 57.00M 66.00M - 70.00M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -3.00000M -381.00000M -333.00000M -607.00000M -238.00000M
Change to liabilities - - - 16.00M 14.00M
Total cashflows from investing activities -402.26624M -381.00000M -333.00000M -607.00000M -238.00000M
Net borrowings 301.00M 124.00M -93.00000M 447.00M -114.00000M
Total cash from financing activities 59.22M -188.00000M -337.00000M -58.00000M -287.00000M
Change to operating activities - - - -49.00000M 84.00M
Net income 410.43M 359.00M 190.00M 233.00M 544.00M
Change in cash 126.14M -17.00000M -65.00000M -156.00000M 103.00M
Begin period cash flow 201.98M 205.00M 270.00M 426.00M 323.00M
End period cash flow 328.12M 188.00M 205.00M 270.00M 426.00M
Total cash from operating activities 366.53M 564.00M 608.00M 530.00M 638.00M
Issuance of capital stock -36.00000M -38.00000M 0.00000M - -
Depreciation 216.45M 197.00M 190.00M 193.00M 145.00M
Other cashflows from investing activities 1.02M -66.00000M -33.00000M -3.00000M -12.00000M
Dividends paid 188.88M 175.00M 137.00M 125.00M 120.00M
Change to inventory -87.80430M -112.00000M -115.00000M -102.00000M 38.00M
Change to account receivables -99.03509M -144.00000M -24.00000M 4.00M -166.00000M
Sale purchase of stock - - 0.00000M -300.00000M -
Other cashflows from financing activities -59.21686M -99.00000M -127.00000M 1692.00M 309.00M
Change to netincome - - - 283.00M 66.00M
Capital expenditures 201.13M 165.00M 169.00M 225.00M 229.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -255.24507M -213.00000M -8.00000M -131.00000M -30.00000M
Stock based compensation 23.00M 27.00M 25.00M 22.00M 29.00M
Other non cash items -5.10490M 194.00M 211.00M 213.00M 39.00M
Free cash flow 165.40M 399.00M 439.00M 305.00M 409.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
HIK
Hikma Pharmaceuticals PLC		 -5.0 0.35% 1416.00 9.73 9.03 0.85 1.45 1.53 6.07
HLN
Haleon PLC		 0.30 0.09% 321.20 20.24 18.94 2.95 2.02 3.68 14.19
HCM
HUTCHMED China Ltd		 1.00 0.57% 175.00 5.38 19.30 3.37 2.02 2.25 2.40
AGY
Allergy Therapeutics		 0.20 2.35% 8.70 - 106.38 11.72 159.47 12.12 -4.1496
ANCR
Animalcare Group Plc		 - -% 331.50 61.50 16.92 2.09 1.43 2.13 14.48

Reports Covered

Stock Research & News

View All

Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.

Hikma Pharmaceuticals PLC

1 New Burlington Place, London, United Kingdom, W1S 2HR

Key Executives

Name Title Year Born
Engineer Said Samih Taleb Darwazah Exec. Chairman & CEO 1957
Mr. Mazen Samih Taleb Darwazah Exec. Vice Chairman & Pres of MENA 1958
Mr. Khalid Waleed Hosny Al Nabilsi Chief Financial Officer 1972
Mr. Hussein Arkhagha Company Sec. & Chief Counsel NA
Mr. Bassam Wael Rushdi Kanaan CFA, CPA Exec. VP of Corp. Devel. and M&A 1965
Ms. Susan Ringdal Exec. VP of Strategic Planning & Global Affairs NA
Ms. Majda Labadi Exec. VP of Organisational Devel. NA
Mr. Riad Mishlawi Pres of Injectables NA
Mr. Brian Hoffmann Pres of Generics NA
Mr. Samuel Park Global Head of Intellectual Property (IP) & Gen. Counsel for US NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.